GB201915282D0 - Specific binding molecules - Google Patents

Specific binding molecules

Info

Publication number
GB201915282D0
GB201915282D0 GB201915282A GB201915282A GB201915282D0 GB 201915282 D0 GB201915282 D0 GB 201915282D0 GB 201915282 A GB201915282 A GB 201915282A GB 201915282 A GB201915282 A GB 201915282A GB 201915282 D0 GB201915282 D0 GB 201915282D0
Authority
GB
United Kingdom
Prior art keywords
specific binding
binding molecules
molecules
specific
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201915282A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunocore Ltd
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Priority to GB201915282A priority Critical patent/GB201915282D0/en
Publication of GB201915282D0 publication Critical patent/GB201915282D0/en
Priority to BR112022007619A priority patent/BR112022007619A2/pt
Priority to IL292358A priority patent/IL292358A/en
Priority to CN202080089240.7A priority patent/CN115052885A/zh
Priority to KR1020227017279A priority patent/KR20220087511A/ko
Priority to PCT/EP2020/079573 priority patent/WO2021078774A1/en
Priority to JP2022523723A priority patent/JP2023522799A/ja
Priority to US17/771,447 priority patent/US20240190969A1/en
Priority to EP20796545.0A priority patent/EP4048684A1/en
Priority to CA3158489A priority patent/CA3158489A1/en
Priority to AU2020369114A priority patent/AU2020369114A1/en
Priority to MX2022004906A priority patent/MX2022004906A/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
GB201915282A 2019-10-22 2019-10-22 Specific binding molecules Ceased GB201915282D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GB201915282A GB201915282D0 (en) 2019-10-22 2019-10-22 Specific binding molecules
MX2022004906A MX2022004906A (es) 2019-10-22 2020-10-21 Moleculas de union especifica.
KR1020227017279A KR20220087511A (ko) 2019-10-22 2020-10-21 특이적 결합 분자
IL292358A IL292358A (en) 2019-10-22 2020-10-21 specific binding molecules
CN202080089240.7A CN115052885A (zh) 2019-10-22 2020-10-21 特异性结合分子
BR112022007619A BR112022007619A2 (pt) 2019-10-22 2020-10-21 Molécula de ligação específica, molécula de fusão de molécula de ligação específica anti-cd3, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou geneticamente modificada, composição farmacêutica, método para tratar um sujeito humano com câncer ou tumor e método para produzir uma molécula de ligação específica
PCT/EP2020/079573 WO2021078774A1 (en) 2019-10-22 2020-10-21 Specific binding molecules
JP2022523723A JP2023522799A (ja) 2019-10-22 2020-10-21 特異的結合性分子
US17/771,447 US20240190969A1 (en) 2019-10-22 2020-10-21 Specific binding molecules
EP20796545.0A EP4048684A1 (en) 2019-10-22 2020-10-21 Specific binding molecules
CA3158489A CA3158489A1 (en) 2019-10-22 2020-10-21 Specific binding molecules
AU2020369114A AU2020369114A1 (en) 2019-10-22 2020-10-21 Specific binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201915282A GB201915282D0 (en) 2019-10-22 2019-10-22 Specific binding molecules

Publications (1)

Publication Number Publication Date
GB201915282D0 true GB201915282D0 (en) 2019-12-04

Family

ID=68728351

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201915282A Ceased GB201915282D0 (en) 2019-10-22 2019-10-22 Specific binding molecules

Country Status (12)

Country Link
US (1) US20240190969A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048684A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522799A (cg-RX-API-DMAC7.html)
KR (1) KR20220087511A (cg-RX-API-DMAC7.html)
CN (1) CN115052885A (cg-RX-API-DMAC7.html)
AU (1) AU2020369114A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007619A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158489A1 (cg-RX-API-DMAC7.html)
GB (1) GB201915282D0 (cg-RX-API-DMAC7.html)
IL (1) IL292358A (cg-RX-API-DMAC7.html)
MX (1) MX2022004906A (cg-RX-API-DMAC7.html)
WO (1) WO2021078774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201901305D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN120302989A (zh) * 2022-10-05 2025-07-11 帝斯肯医疗公司 Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
KR20250133715A (ko) 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
IL321809A (en) 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
DK1247095T3 (da) 1999-12-06 2008-12-08 Univ Illinois TCR-proteiner med höj affinitet samt fremgangsmåder
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
PT2951202T (pt) * 2013-01-29 2020-07-07 Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch Moléculas de ligação de alta avidez que reconhecem mage-a1
CN106749620B (zh) 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
IL308831A (en) * 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
AU2018234830B2 (en) 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
CN109081867B (zh) * 2017-06-13 2021-05-28 北京大学 癌症特异性tcr及其分析技术和应用
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule

Also Published As

Publication number Publication date
MX2022004906A (es) 2022-05-25
WO2021078774A1 (en) 2021-04-29
BR112022007619A2 (pt) 2022-07-12
CA3158489A1 (en) 2021-04-29
US20240190969A1 (en) 2024-06-13
EP4048684A1 (en) 2022-08-31
CN115052885A (zh) 2022-09-13
AU2020369114A1 (en) 2022-04-28
JP2023522799A (ja) 2023-06-01
KR20220087511A (ko) 2022-06-24
IL292358A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL281901A (en) Multivalent binding compounds based on IgM and IgA-Fc
IL273631A (en) Special hpv molecules bind
GB201901305D0 (en) Specific binding molecules
IL275510A (en) Specific antigen-binding molecules-ROR1
GB201901306D0 (en) Multi-domain binding molecules
IL289867A (en) Immunostimulatory multisegmented binding compounds
GB201811408D0 (en) CD137 Binding Molecules
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
IL289415A (en) Claudin-6 binding molecules and their use
IL287555A (en) binding compounds
GB201612520D0 (en) Binding molecules
GB201811410D0 (en) OX40 Binding molecules
GB202006629D0 (en) Specific binding molecules
GB201702091D0 (en) Specific binding molecules
SG11202109535SA (en) Cd3 binding molecules
IL288561A (en) gal9-binding molecules with immunosuppressive activity
IL289266B1 (en) New molecules
IL269752B (en) fgfr3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201904328D0 (en) Specific binding molecules
EP3976199A4 (en) ACTIVATION OF ANTI-GAL9 ANTIBODY BINDING MOLECULES
ZA202200734B (en) Binding members
GB201912657D0 (en) Binding members

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)